Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...

A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.